Literature DB >> 34033103

Detection of Immunogenic Cell Death in Tumor Vaccination Mouse Model.

Kazuki Tatsuno1, Patrick Han2, Richard Edelson3, Douglas Hanlon3.   

Abstract

Immunogenic cell death (ICD) is a form of regulated cell death that is capable of eliciting an immune response. In cancer, tumor cells undergoing ICD are known to emit damage associated molecular patterns (DAMPs) that are capable of recruiting and activating antigen presenting cells (APCs), which ultimately lead to the activation of an antitumor immune response. Surface translocation of intracellular chaperones such as calreticulin, release of TLR agonists such as high mobility box 1, and the secretion of type I IFN are some of the hallmark features seen in tumors succumbing to ICD. While detection of these molecules is suggestive of ICD induction, which alone does not certify that the treatment is an ICD inducer, an in vivo vaccination assay using injured tumor cells remains to be the gold standard method to functionally verify ICD. This chapter will discuss the necessary steps required to conduct an in vivo vaccination assay, focusing on the preparation of vaccine using treated tumor cells, and how these cells are then utilized in the animal model.

Entities:  

Keywords:  Clonogenic cell death; Colony formation assay; DAMPs; Immunogenic cell death; Murine tumor model; Tumor vaccination

Year:  2021        PMID: 34033103     DOI: 10.1007/978-1-0716-1162-3_15

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  21 in total

1.  Immunogenic death of colon cancer cells treated with oxaliplatin.

Authors:  A Tesniere; F Schlemmer; V Boige; O Kepp; I Martins; F Ghiringhelli; L Aymeric; M Michaud; L Apetoh; L Barault; J Mendiboure; J-P Pignon; V Jooste; P van Endert; M Ducreux; L Zitvogel; F Piard; G Kroemer
Journal:  Oncogene       Date:  2009-11-02       Impact factor: 9.867

2.  Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy.

Authors:  Christina Pfirschke; Camilla Engblom; Steffen Rickelt; Virna Cortez-Retamozo; Christopher Garris; Ferdinando Pucci; Takahiro Yamazaki; Vichnou Poirier-Colame; Andita Newton; Younes Redouane; Yi-Jang Lin; Gregory Wojtkiewicz; Yoshiko Iwamoto; Mari Mino-Kenudson; Tiffany G Huynh; Richard O Hynes; Gordon J Freeman; Guido Kroemer; Laurence Zitvogel; Ralph Weissleder; Mikael J Pittet
Journal:  Immunity       Date:  2016-02-09       Impact factor: 31.745

3.  Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin.

Authors:  Abhishek D Garg; Dmitri V Krysko; Peter Vandenabeele; Patrizia Agostinis
Journal:  Cancer Immunol Immunother       Date:  2011-12-23       Impact factor: 6.968

Review 4.  Induction of abscopal anti-tumor immunity and immunogenic tumor cell death by ionizing irradiation - implications for cancer therapies.

Authors:  B Frey; Y Rubner; R Wunderlich; E-M Weiss; A G Pockley; R Fietkau; U S Gaipl
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

5.  Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications.

Authors:  Radek Spisek; Anna Charalambous; Amitabha Mazumder; David H Vesole; Sundar Jagannath; Madhav V Dhodapkar
Journal:  Blood       Date:  2007-02-13       Impact factor: 22.113

6.  The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death.

Authors:  Chiara Pozzi; Alessandro Cuomo; Ilaria Spadoni; Elena Magni; Alessio Silvola; Alexia Conte; Sara Sigismund; Paola Simona Ravenda; Tiziana Bonaldi; Maria Giulia Zampino; Carlotta Cancelliere; Pier Paolo Di Fiore; Alberto Bardelli; Giuseppe Penna; Maria Rescigno
Journal:  Nat Med       Date:  2016-05-02       Impact factor: 53.440

7.  Measles virus causes immunogenic cell death in human melanoma.

Authors:  O G Donnelly; F Errington-Mais; L Steele; E Hadac; V Jennings; K Scott; H Peach; R M Phillips; J Bond; H Pandha; K Harrington; R Vile; S Russell; P Selby; A A Melcher
Journal:  Gene Ther       Date:  2011-12-15       Impact factor: 5.250

8.  Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death.

Authors:  Noelia Casares; Marie O Pequignot; Antoine Tesniere; François Ghiringhelli; Stéphan Roux; Nathalie Chaput; Elise Schmitt; Ahmed Hamai; Sandra Hervas-Stubbs; Michel Obeid; Frédéric Coutant; Didier Métivier; Evelyne Pichard; Pierre Aucouturier; Gérard Pierron; Carmen Garrido; Laurence Zitvogel; Guido Kroemer
Journal:  J Exp Med       Date:  2005-12-19       Impact factor: 14.307

9.  Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity.

Authors:  Mikako Ogawa; Yusuke Tomita; Yuko Nakamura; Min-Jung Lee; Sunmin Lee; Saori Tomita; Tadanobu Nagaya; Kazuhide Sato; Toyohiko Yamauchi; Hidenao Iwai; Abhishek Kumar; Timothy Haystead; Hari Shroff; Peter L Choyke; Jane B Trepel; Hisataka Kobayashi
Journal:  Oncotarget       Date:  2017-02-07

10.  Extracorporeal photochemotherapy induces bona fide immunogenic cell death.

Authors:  Kazuki Tatsuno; Takahiro Yamazaki; Douglas Hanlon; Patrick Han; Eve Robinson; Olga Sobolev; Alp Yurter; Felix Rivera-Molina; Najla Arshad; Richard L Edelson; Lorenzo Galluzzi
Journal:  Cell Death Dis       Date:  2019-08-02       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.